For years, pharma launch success was judged by a single metric: performance in the first 12 months.
That benchmark no longer reflects reality.
Today’s commercial environment has fundamentally reshaped what launch success looks like. Payer control has intensified. Provider adoption is slower. Patients are more involved in treatment decisions — yet face greater access and affordability barriers. The result is clear: launches that once followed a 12-month sprint now unfold over a 36-month trajectory.
IQVIA’s latest analysis underscores the shift. Only one in 10 recent launches exceeded $100 million in its first year — down from one in five just a few years ago. Yet many organizations still evaluate performance using outdated expectations.
The disconnect isn’t in the science. It’s in the timeline.
Launch Conditions Have Permanently Shifted
Across therapeutic areas, brands are facing a more complex and restrictive commercial landscape:
- Payers are tightening control, driving higher rejection and abandonment rates.
- Provider adoption is slower, with IQVIA noting that in oncology, only ~20% of HCPs adopt a new therapy within two years.
- Patients are more influential, but their ability to act is constrained by coverage gaps, cost pressures, and fragmented information.
These are not temporary headwinds. They are structural changes.
Deloitte reports that one-third of U.S. drug launches fail to meet expectations. ZS Associates finds that 40–60% of analyst forecasts underperform. L.E.K. Consulting notes that more than half of launches fail to reach even $250 million in peak revenue.
The sources vary. The conclusion does not: launch strategy must evolve.
The 36-Month Launch Window: A More Realistic Benchmark
Perhaps the clearest signal of change is IQVIA’s recommendation to expand the definition of launch success from 12 months to 36 months. This longer horizon mirrors how markets actually behave.
Year 1: Awareness + Access Groundwork
Brands establish credibility, shape coverage decisions, and build foundational understanding. Early traction is often limited by access friction.
Year 2: Adoption Lift + Formulary Progress
Provider behavior begins to shift more meaningfully. Payer decisions improve coverage clarity, reducing barriers.
Year 3: Momentum + Market Expansion
Brands often reach their true growth curve and accelerate toward peak performance.
In today’s environment, a slower first year does not signal failure. It signals alignment with modern market dynamics.
Three Forces Reshaping Launch Strategy
1. Payer Control and Access Friction
In an era of rising costs and scrutiny, even strong clinical profiles encounter structural barriers.
What brand teams must do:
- Engage payers earlier in the pre-launch phase
- Equip field teams with robust economic and outcomes evidence
- Develop scenario plans for restrictive or delayed formulary placement
- Sequence promotional investment based on access readiness
Launching without access alignment is no longer viable.
2. Provider Adoption Lag
Healthcare providers face information overload and mounting administrative pressure. Shifts in prescribing behavior can take up to two years in many therapeutic categories.
- Design multi-year, multi-touch engagement strategies
- Leverage EHR integration, professional networks, and peer-to-peer programs
- Monitor behavioral indicators such as content engagement and diagnostic trends
- Ensure education evolves alongside data and access changes
Sustained engagement beats short-term intensity.
3. Patient Activation in a Complex Ecosystem
Patients are increasingly involved in treatment decisions, particularly in chronic and lifestyle-adjacent categories. But curiosity does not equal conversion if coverage and provider alignment lag behind.
- Time patient campaigns to align with real-world access
- Provide transparent, practical information on affordability and initiation
- Use precision digital channels to drive informed engagement
- Support both patients and caregivers through simplified pathways
Demand generation must be synchronized with system readiness.
A Practical Framework for Modern Launch Teams
At Silverlight, we see the most resilient launches share several common characteristics:
Expand the horizon.
Adjust internal expectations, forecasting models, and KPIs to align with a 36-month adoption curve.
Synchronize stakeholders.
Payer, provider, and patient strategies must operate in parallel — not in sequence. Misalignment is one of the most common drivers of early underperformance.
Pace investment strategically.
Avoid front-loading budgets based on outdated benchmarks. Align media and promotional spend with access milestones and adoption inflection points.
Shift from volume to precision
Mass awareness alone is insufficient. Precision education — through search, programmatic, HCP platforms, and contextually relevant channels — drives more informed action.
Build in agility.
Real-time data should inform adjustments in messaging, channel mix, and targeting. Waiting a full year to recalibrate is too slow.
Strengthen cross-functional alignment.
Commercial, medical, market access, and insights teams must operate from a shared, multi-year roadmap.
What Success Looks Like Now
Modern launch success is defined less by early acceleration and more by strategic resilience:
- Steadier, longer adoption curves
- Growing reliance on real-world evidence
- Digital ecosystems supporting education and engagement
- Market share acceleration beginning in Year 3
- Flexible budgets that adapt to access realities
Brands that recognize these patterns early are better positioned for durable growth.
The Bottom Line
Launch success hasn’t disappeared. It has matured.
What used to be a sprint is now a coordinated, multi-year effort requiring alignment across payers, providers, and patients. Clinging to the 12-month benchmark risks undermining otherwise strong brands.
The organizations that recalibrate expectations — and redesign their launch architecture accordingly — will define the next generation of commercial excellence in pharma.
This article was previously published on PharmaLive / Med Ad News.
